Risk sharing: Pharma's failure to prove its value
This article was originally published in Scrip
Executive Summary
Risk sharing deals are popular in the UK and now in the US, but some government bodies view them as a way for companies to establish higher prices elsewhere. Francesca Bruce, Scrip's Europe reporter, discovers that they may not be a viable business model.